Neurosurgical treatment and outcome patterns of meningioma in Sweden: a nationwide registry-based study.
Health registry
Meningioma
Neurosurgery
Population-based
Journal
Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
20
10
2018
accepted:
04
01
2019
pubmed:
25
1
2019
medline:
25
1
2020
entrez:
25
1
2019
Statut:
ppublish
Résumé
Surgery is the main treatment modality for intracranial meningiomas, but data on short-term surgical outcome are limited. The aim of this Swedish nationwide registry-based study was to benchmark the 30-day complication rate in a cohort of meningioma patients using data from the Swedish brain tumor registry (SBTR). Furthermore, we investigated outcomes for asymptomatic patients. Data were collected from the SBTR for all adults with histopathologically verified intracranial meningioma between 2009 and 2015. Patient symptoms, tumor characteristics, and complications within 30 days postoperatively were analyzed. In total, 2324 patients, with a mean age of 58.7 years (SD 13.5), underwent surgery for intracranial meningioma and 14.1% of the patients were asymptomatic before the intervention. The most common symptom prior to treatment was focal deficit, which occurred in 1450 patients (62.4%). Moreover, within 30 days after surgery, 344 patients (14.8%) developed new neurological deficits and new-onset seizures occurred in 105 patients (4.5%), while 8.3% of asymptomatic patients developed neurological deficit and 3.7% new-onset seizures. Due to complications, reoperations were performed in 120 patients (5.2%). The postoperative 30-day mortality in the whole cohort was 1.5%. This study benchmarks the 30-day complication rate after meningioma surgery and provides outcome data in the highly relevant group of asymptomatic patients using data from the Swedish brain tumor registry. Since surgical decision-making is a careful consideration of short-term risk versus long-term benefit, this information may be useful for both caregivers and patients.
Sections du résumé
BACKGROUND
Surgery is the main treatment modality for intracranial meningiomas, but data on short-term surgical outcome are limited. The aim of this Swedish nationwide registry-based study was to benchmark the 30-day complication rate in a cohort of meningioma patients using data from the Swedish brain tumor registry (SBTR). Furthermore, we investigated outcomes for asymptomatic patients.
METHODS
Data were collected from the SBTR for all adults with histopathologically verified intracranial meningioma between 2009 and 2015. Patient symptoms, tumor characteristics, and complications within 30 days postoperatively were analyzed.
RESULTS
In total, 2324 patients, with a mean age of 58.7 years (SD 13.5), underwent surgery for intracranial meningioma and 14.1% of the patients were asymptomatic before the intervention. The most common symptom prior to treatment was focal deficit, which occurred in 1450 patients (62.4%). Moreover, within 30 days after surgery, 344 patients (14.8%) developed new neurological deficits and new-onset seizures occurred in 105 patients (4.5%), while 8.3% of asymptomatic patients developed neurological deficit and 3.7% new-onset seizures. Due to complications, reoperations were performed in 120 patients (5.2%). The postoperative 30-day mortality in the whole cohort was 1.5%.
CONCLUSION
This study benchmarks the 30-day complication rate after meningioma surgery and provides outcome data in the highly relevant group of asymptomatic patients using data from the Swedish brain tumor registry. Since surgical decision-making is a careful consideration of short-term risk versus long-term benefit, this information may be useful for both caregivers and patients.
Identifiants
pubmed: 30675656
doi: 10.1007/s00701-019-03799-3
pii: 10.1007/s00701-019-03799-3
pmc: PMC6373228
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-341Subventions
Organisme : Vetenskapsr?det
ID : 2017-00944
Pays : International
Organisme : ALF-funding
ID : ALFGBG-716671
Pays : International
Références
Lancet Oncol. 2016 Sep;17(9):e383-91
pubmed: 27599143
PLoS One. 2015 Apr 27;10(4):e0124534
pubmed: 25915782
J Neurosci Rural Pract. 2014 Jul;5(3):244-9
pubmed: 25002762
World Neurosurg. 2017 Jan;97:538-546
pubmed: 27777150
J Neurosurg. 2011 Mar;114(3):705-9
pubmed: 20578801
Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1
pubmed: 12823874
J Neurosurg. 1998 May;88(5):831-9
pubmed: 9576250
Neurosurgery. 1993 Apr;32(4):643-57
pubmed: 8474655
Cancer. 2015 Dec 15;121(24):4376-81
pubmed: 26308667
Neuro Oncol. 2012 May;14(5):658-66
pubmed: 22406926
World Neurosurg. 2017 Oct;106:145-151
pubmed: 28666914
Cancer. 2018 Feb 15;124(4):734-742
pubmed: 29131312
Acta Neurochir (Wien). 2015 Sep;157(9):1549-57; discussion 1557
pubmed: 26170189
World Neurosurg. 2015 May;83(5):673-8
pubmed: 25655686
World Neurosurg. 2018 Apr;112:e702-e710
pubmed: 29408648
Neurosurg Rev. 2015 Jul;38(3):481-8; discussion 488
pubmed: 25697143
J Neurosurg. 2011 Sep;115(3):483-90
pubmed: 21639698
Epilepsy Res. 2000 Jan;38(1):45-52
pubmed: 10604605
J Neurosurg. 2016 Jun;124(6):1552-61
pubmed: 26636386
Neurol Res. 2004 Jan;26(1):61-6
pubmed: 14977059
J Neurosurg. 2011 Mar;114(3):697-704
pubmed: 20653395
J Neurosurg. 2015 Oct;123(4):972-7
pubmed: 26252464
Acta Oncol. 2015 Mar;54(3):377-84
pubmed: 25383446
Br J Neurosurg. 1999 Feb;13(1):52-5
pubmed: 10492685
Clin Neurol Neurosurg. 2014 Aug;123:150-4
pubmed: 24956544
Neuro Oncol. 2016 Jul;18(7):1002-10
pubmed: 26683139
Neuro Oncol. 2017 Nov 6;19(suppl_5):v1-v88
pubmed: 29117289
J Neurosurg. 2000 May;92(5):766-70
pubmed: 10794289
JAMA. 2014 Apr 23-30;311(16):1661-9
pubmed: 24756516
Neurosurg Focus. 2011 Dec;31(6):E19
pubmed: 22133182
Neurosurg Focus. 2007;23(4):E1
pubmed: 17961033
Lancet. 2004 May 8;363(9420):1535-43
pubmed: 15135603
Surg Neurol. 2001 Jul;56(1):8-20; discussion 20-1
pubmed: 11546562
Neurosurgery. 2011 May;68(5):1259-68; discussion 1268-9
pubmed: 21273920
J Clin Oncol. 2012 Jul 10;30(20):2559-65
pubmed: 22529254
J Surg Oncol. 2014 Jun;109(7):629-30
pubmed: 24464362
World Neurosurg. 2016 Apr;88:320-326
pubmed: 26746334
Neurosurgery. 2008 Sep;63(3):427-33; discussion 433-4
pubmed: 18812953
J Neurosurg. 1984 Jan;60(1):52-60
pubmed: 6689728
J Neurosurg. 2014 Apr;120(4):827-32
pubmed: 24484230
JAMA. 2012 Nov 14;308(18):1881-8
pubmed: 23099483
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Acta Neurochir (Wien). 2006 Dec;148(12):1257-65; discussion 1266
pubmed: 17086473
Acta Neurochir (Wien). 2015 Feb;157(2):225-30; discussion 230
pubmed: 25503298